Baseline characteristics and transplantation outcomes
| Variable | Total (n=20 971) | Sarcoid (n=695, 3.3%) | Non-sarcoid (n=20 201, 96.7%) | p Value |
|---|---|---|---|---|
| Pretransplant | ||||
| Age, year, mean±SD | 50.2±15.0 | 49.9±8.7 | 50.2±15.1 | 0.55 |
| Males, n (%) | 11 165 (53.2) | 300 (43.0) | 10 865 (53.6) | <0.001 |
| Caucasian, n (%) | 18 309 (87.3) | 227 (32.6) | 18 082 (89.2) | <0.001 |
| Waiting time, month, median (range) | 5.3 (0–195) | 5.9 (0–97) | 5.3 (0–195) | 0.24 |
| Life support, n (%) | ||||
| Inhaled NO | 18 (0.1) | 0 (0) | 18 (0.1) | 0.43 |
| Prostacyclin | 63 (0.3) | 4 (0.5) | 59 (0.3) | 0.41 |
| ECMO-bridge | 43 (0.2) | 0 (0) | 43 (0.2) | 0.22 |
| Mechanical ventilation | 312 (1.5) | 5 (0.7) | 307 (1.5) | 0.10 |
| Transplant | ||||
| Graft ischemic time, hour, mean±SD | 4.8±1.7 | 5.1±1.8 | 4.8±1.7 | <0.001 |
| Double lung transplant, n (%) | 12 011 (57.3) | 480 (68.9) | 11 531 (56.9) | <0.001 |
| Donor | ||||
| Age, year, mean±SD | 31.9±14.2 | 33.7±13.7 | 31.8±14.1 | <0.001 |
| Male, n (%) | 12 861 (61.3) | 369 (52.9) | 12 492 (61.6) | <0.001 |
| Caucasian, n (%) | 14 285 (68.1) | 432 (62) | 13 853 (68.3) | <0.001 |
| LAS era, post, n (%) | 10 245 (49.0) | 381 (54.8) | 9864 (48.8) | 0.002 |
| Post-transplant | ||||
| Survival | ||||
| Median (IQR), months | 63.4 (61.7–65.0) | 69.7 (60.2–79.3) | 63.1 (61.4–64.8) | 0.88 |
| 1 year (%) | 72 | 71 | 73 | |
| 5 years (%) | 47 | 50 | 46 | |
| 10 years (%) | 26 | 28 | 26 | |
| Allograft dysfunction | ||||
| Retransplanted, n (%) | 787 (3.8) | 15 (2.2) | 772 (3.8) | 0.03 |
| BOS, n (%) | 7283 (35.6) | 222 (31.9) | 7061 (35.7) | 0.42 |
| New O2 requirement, n (%) | 1065 (27.8) | 129 (27.5) | 3936 (27.8) | 0.9 |
Prostacyclin in the intravenous or inhaled formulations.
BOS, post-transplant bronchioalveolitis obliterans syndrome; ECMO, extracorporeal membrane oxygenation; LAS, lung allocation score; NO, inhaled nitric oxide.